Effect of RAS blockers on hematocrit. (A) Percentage of hematocrit change in fosinoprilate- and Sar1-Ile8-Ang II–treated embryos, relative to control embryos. Embryos treated with fosinoprilate (Fos, ) at stage HH11 (n = 19) or at stage HH13 (n = 8), and embryos treated with Sar1-Ile8-Ang II (Sar, □) at stage HH11 (n = 13) or at stage HH13 (n = 7), in comparison to control embryos treated with vehicle only at stage HH11 (n = 17) or at stage HH13 (n = 8). (B) Dose-dependent effect of Sar1-Ile8-Ang II on hematocrit. Results are expressed as a percentage of control hematocrit values (c, n = 32, ▪), in embryos treated with 0.1 mg/mL (n = 7) or 0.3 mg/mL (n = 16) Sar-Ile8-Ang II (□). Each bar is a mean ± SEM. *P = .006, **P < .002, and ***P < .001.